Side-by-side · Research reference

Kisspeptin-10vsTriptorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/41 cited

BFDA-ApprovedHUMAN-REVIEWED16/64 cited

Kisspeptin-10

Neuropeptide · GPR54 Agonist

GnRH pulse generatorPrimary roleSilva 2026

Phase 1/2Clinical stage

GPR54/Kiss1RTarget receptorRønnekleiv 2026

IV / SQ · Investigational

Triptorelin

GnRH Agonist · FDA-Approved

3.75–22.5 mgDepot dose rangeYee 2025 Chen 2024

<50 ng/dLTestosterone target

1–6 monthsDepot durationYee 2025 Chen 2024

IM · Depot Injection · Monthly to 6-MonthlyYee 2025

01Mechanism of Action

Parameter

Kisspeptin-10

Triptorelin

Primary target

GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026 Collado-Sole 2026

Pituitary GnRH receptorsUnknown 2012

Pathway

Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026 Rønnekleiv 2026

GnRH receptor agonism → initial flare (LH/FSH spike) → receptor desensitization → sustained LH/FSH suppression

Downstream effect

Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026

Castration-level suppression of testosterone (men) and estrogen (women) within 2–4 weeks post-flare

Feedback intact?

Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026 Rønnekleiv 2026

No — bypasses physiological pulsatility; continuous agonism produces paradoxical suppression

Origin

C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms

Synthetic decapeptide analogue of native GnRH with amino acid substitutions for enhanced receptor affinity and stability

Antibody development

—

02Dosage Protocols

Parameter

Kisspeptin-10

Triptorelin

Clinical trial dose

Phase 1/2 investigational

Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).

—

Route

IV or SQ administration

IV preferred in controlled trials for precise pulsatile delivery.

—

Evidence basis

Phase 1/2 trials

Multiple Phase 3 RCTs · FDA-approved 1999

Half-life

Short (minutes)

Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.

—

1-month depot

—

3.75 mg IM

Most common formulation for prostate cancer.

3-month depot

—

11.25 mg IMYee 2025

Reduced injection frequency.

6-month depot

—

22.5 mg IMYee 2025 Chen 2024

Long-acting formulation; improved adherence in real-world use.Yee 2025

Administration route

—

Intramuscular (IM) — gluteal or deltoid

Frequency

—

Every 1, 3, or 6 months per formulation

Indication: Prostate cancer

—

Advanced (metastatic or locally advanced)

Androgen deprivation therapy (ADT) backbone.

Indication: Endometriosis

—

3.75 mg monthly

FDA-approved; typically 6-month course.

Indication: Central precocious puberty

—

Pediatric use (≥2 years)Jia 2025

Weight-based dosing per FDA label.

Duration (prostate cancer)

—

Continuous or intermittent ADT protocolsPreston 2024

Intermittent ADT may reduce side effects; cardiovascular risk similar to continuous.

Monitoring

—

Serum testosterone, PSA (prostate cancer), bone density, lipids, glucose

04Side Effects & Safety

Parameter

Kisspeptin-10

Triptorelin

Ovarian hyperstimulation

Theoretical risk with supraphysiological dosing in fertility protocols

—

Headache

Mild, reported in early-phase trials

—

Nausea

Transient GI symptoms with IV bolus

—

Hot flashes

Vasomotor symptoms from LH surge

Very common (>60%); vasomotor instability

Injection site reaction

Erythema, mild discomfort (SQ route)

—

Initial flare symptoms

—

Bone pain, urinary obstruction, spinal cord compression (first 2 weeks)

Antiandrogen co-treatment (bicalutamide) mitigates flare in metastatic disease.

Cardiovascular events

—

MI, stroke, arrhythmia — GnRH agonists show higher CV risk vs antagonists in meta-analysesPatel 2025 Preston 2024

Bone loss / Osteoporosis

—

Accelerated bone mineral density decline; fracture risk ↑Friedrich 2025

Baseline DEXA scan recommended; bisphosphonates or denosumab may be indicated.

Metabolic syndrome

—

Weight gain, insulin resistance, dyslipidemia, diabetes risk

Sexual dysfunction

—

Erectile dysfunction, loss of libido (expected pharmacological effect)Jia 2025

Injection site reactions

—

Pain, erythema, sterile abscess (rare with depot formulations)

Gynecomastia / Breast tenderness

—

Common (10–20%); peripheral aromatization of residual androgens

Fatigue / Mood changes

—

Anemia, depression, cognitive changes reported in long-term ADT

Hepatotoxicity

—

Transient transaminase elevations; clinically apparent liver injury rare

Racial differences (ADT)

—

Black veterans show higher CV event rates vs White veterans on GnRH agonists

Absolute Contraindications

Kisspeptin-10

·Active pregnancy
·Hormone-sensitive malignancy (breast, ovarian, endometrial)

Triptorelin

·Hypersensitivity to triptorelin, GnRH, or GnRH agonist analogues
·Pregnancy (Category X)

Relative Contraindications

Kisspeptin-10

·Polycystic ovary syndrome (PCOS) without monitoring
·Uncontrolled thyroid dysfunction

Triptorelin

·Active cardiovascular disease — consider GnRH antagonist alternative
·Metastatic vertebral disease with spinal cord compression risk (flare hazard)
·Severe urinary obstruction — may worsen during flare
·Osteoporosis or high fracture risk (requires bone-protective therapy)

05Administration Protocol

Parameter

Kisspeptin-10

Triptorelin

1. Reconstitution (if lyophilized)

Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.

Choose 1-month (3.75 mg), 3-month (11.25 mg), or 6-month (22.5 mg) depot based on adherence needs and clinical context. 6-month formulation shows improved real-world adherence in Asia-Pacific cohorts.

2. Route selection

IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.

Intramuscular — gluteal or deltoid muscle. Use 21–23G needle. Aspirate to confirm non-vascular placement. Rotate sites with repeat injections.

3. Timing

Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.

For metastatic prostate cancer: co-administer antiandrogen (e.g., bicalutamide 50 mg daily) starting 1 week before first injection and continuing 2–4 weeks to prevent tumor flare.

4. Monitoring

Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.

Baseline: testosterone, PSA, bone density (DEXA), lipids, glucose. Follow-up: testosterone at 4 weeks (confirm <50 ng/dL castration), PSA monthly × 3, then quarterly. Annual DEXA for bone loss.

5. Storage

Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.

Store vials at room temperature (20–25 °C), protect from light. Do not freeze. Reconstituted suspension should be used immediately.

6. Intermittent ADT protocol (optional)

—

Some protocols use on-treatment periods (9–12 months) alternating with off-treatment intervals until PSA rises. Cardiovascular risk appears similar to continuous ADT.